Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We, Kiura, Katsuyuki, Inoue, Akira, Takeda, Koji, Kang, Jin‐Hyoung, Nakagawa, Tomoki, Takeda, Kentaro, Akazawa, Rio, Kaneko, Yuichiro, Shimazaki, Masashi, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125469/
https://ncbi.nlm.nih.gov/pubmed/29972716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13724
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars